GL1X · GenesisL1 explorer

MolNFT v1 · #156043 · protein

Human cgas catalytic domain bound with the inhibitor pf-06928215

6LRC · Cyclic gmp-AMP synthase: “Human cgas catalytic domain bound with the inhibitor pf-06928215”. X-ray diffraction, 2 ligands (KHM, ZN), 9 pockets (best druggability 0.77). MolNFT v1 #156043 on GenesisL1: 3D structure, binding sites and…

PDB
6LRC
Type
protein
Length
701 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Cyclic gmp-AMP synthase
EC
2.7.7.86
UniProt
Q8N884
Ligands
KHM, ZN
Pockets
9 · best druggability 0.77

Structure

x-ray diffraction · 2 distinct chains · 46% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
BCyclic gmp-AMP synthase (EC 2.7.7.86)protein34847% helix, 18% strandQ8N884
ACyclic gmp-AMP synthase (EC 2.7.7.86)protein35345% helix, 18% strandQ8N884

Ligands and binding sites

  • KHM · (1R,2S)-2-[(7-hydroxy-5-phenylpyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]cyclohexane-1-carboxylic acid · ligand · 2 copies · chains B, A
  • ZN · Zinc ion · metal · 2 copies · chains B, A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

9 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
19130.770.7968KHM
26860.750.8056KHM
33190.630.7931empty
41720.460.7535empty
51260.360.7325empty

Interfaces

1 interface between chains.

  • B–A · 723 Ų buried · 19 hydrogen bonds · protein-protein

Compared structures

  • 6LRC · Human cGAS catalytic domain bound with the inhibitor PF-06928215 · the same entry in another collection · chain B against B, TM-score 1.00
  • Q8N884 · AlphaFold monomer V2.0 prediction for cyclic gmp-AMP synthase (Q8N884) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.